Articles On Orthocell (ASX:OCC)

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Regenerative medicine company Orthocell (ASX:OCC) has announced that the Autologous Tenocyte Injection rotator cuff tendon study database has been locked.

“This is an important development milestone for OrthoATI® and the company and I am delighted to have reached this pivotal stage of the study,” says MD.

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Turn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but not quite in the way the 1960s counter-culture figure Dr Timothy Leary intended. The late Harvard psychologist strongly advocated the use of...

Orthocell’s CelGro platform forms the basis of a specialised collagen ‘rope’ that could help reconstruct the anterior cruciate ligament, a strong band of tissue linking the thigh and shin bones that can rupture during athletic activity.

The biggest director trade on the ASX in the past fortnight came from one of Australia’s most famous pub barons – Bruce Mathieson of Endeavour Group (ASX:EDV). Mathieson is 63rd on the Top 22 rich list with a net worth of $1.54 billion. End...

The regenerative medicine company could be on the verge of developing the first off-the-shelf biological device used to treat ACL injuries, a market linked to a growing health economic burden.

The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo...

Highlights  The ASX 200 closed marginally higher on Tuesday despite the Reserve Bank of Australia (RBA) announced its plans to start reducing the bond buying. The ASX 200 closed 0.02% higher at 7,530.30 after rallying towards the close...

The company’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional (direct suture) repair method.

Highlights The ASX 200 was trading flat at 7,536.9 by lunchtime. A-VIX, which shows the volatility of the Australian share market, is trading 4.1% down at 10.88. Aussie Broadband plans to raise AU$120 million for the purpose of accele...

ShareCafeAustralia… One Hour In… ASX200 down 74 ASX200 down 24 points (0.3%) to 7504.   Reserve Bank interest rate decision due at 2.30pm.   Aussie Broadband (TH);  Trading Halt for $120m cap raising. Amcor (-1.1%); ex div 15.93c.  Trading...

Regenerative medicine company Orthocell (ASX:OCC) has announced that new patents have been granted in Canada and Hong Kong for its novel CelGro collagen medical device platform for soft tissue regeneration applications.

Regenerative medicine company Orthocell (ASX:OCC) has announced that the last patient in the Autologous Tenocyte Injection rotator cuff tendon study has completed their 12-month follow-up visit.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

“This is an important development milestone for Ortho-ATI and the company, representing the first randomised controlled trial for a tendon cell therapy to be completed for this indication globally,” says MD.

The regenerative medicine company focused on advancing its CelGro® and Ortho-ATI® pipelines during FY21, ending the period with more than $16 million in the bank.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Local markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday as some major M&A activity stole the headlines. Gains were led by the tech sector, as Afterpay (ASX:APT) showed its weight by dragging th...

The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema.

The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat...

The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial using the Ortho-API® product anticipated this...

The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial using the Ortho-ATI® product anticipated this...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Summary Kirkland (ASX:KLA) reports record production in second quarter 2021 Finbar (ASX:FRI) rises after forecasting 18% jump in FY net profit Pearl Global (ASX:PG1) climbs on supply deal with Alex Fraser The S&P/ASX200 closed...

The company believes SMT is the ideal partner for the Australian market, with its established relationships with oral surgeons and a successful track record driving market entry of high-quality products.

Shares in Perth-based regenerative medicine company Orthocell are climbing on news it has appointed an Australian distributor for its product for bone and soft tissue repair.

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the first interim data of all patients in the CelGro nerve regeneration trial at 12 months post-treatment.

Twelve months on from Orthocell’s CelGro® nerve regeneration trial, a data readout has indicated more than three-quarters of all nerve repairs conducted during the clinical study resulted in functional recovery.

The Orthocell Ltd (ASX: OCC) share price is gaining in morning trade, up 3.3%. Below we take a look at the regenerative medicine company’s latest clinical update. What did Orthocell report? Orthocell’s share price is gaining after the comp...

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand patents have been granted for its CelGro collagen medical device platform for soft tissue regeneration applications.

Summary Commonwealth Bank (ASX:CBA) sets new high, adds nearly A$7 billion in value over 3 weeks Orthocell (ASX:OCC) gets patents for suture-less repair of soft tissue AF Legal Group (ASX:AFL) completes Watts McCray acquisition...

Summary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. The index closed 6.70 points higher at 7,386.20 ahead of the US Fed meeting scheduled tonight. The widely anticipated US Fed policy statement...

The patents cover the method of using CelGro® to repair a defect in soft tissue, such as tendons, ligaments and nerves, avoiding the use of damaging sutures.

The Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it’s at 57.5 cents, up by 1.77%, settling back after jumping 4% in early trading. Let’s have a look at the latest announcement from the regenerative medici...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and Hong Kong patents have been granted for its novel CelGro collagen rope device, to augment the surgical repair of anterior cruciate ligament injuries.